- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.12.25 | ViroGates A/S: ViroGates announces financial guidance for 2026 | 131 | GlobeNewswire (Europe) | Company Announcement no. 22/2025 (December 12, 2025)
BIRKERØD, DENMARK-ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for measuring chronic inflammation... ► Artikel lesen | |
| 28.11.25 | ViroGates A/S: ViroGates' capital raise of DKK 19.3 million and issue of 1,547,412 shares have been registered and settled | 323 | GlobeNewswire (Europe) | Company Announcement no. 21/2025 (November 28, 2025)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company") announces that the capital raise of approximately DKK 19.3 million and the issue... ► Artikel lesen | |
| 26.11.25 | ViroGates A/S - increase | 146 | GlobeNewswire | New shares in ViroGates A/S will be admitted to trading on Nasdaq First North Growth Market Denmark as of 28 November 2025. New shares are issued due to a directed issue of new shares.
Name:
ViroGates
ISIN:
DK0061030574
Short... ► Artikel lesen | |
| 12.11.25 | ViroGates A/S - Observation status | 147 | GlobeNewswire | Nasdaq Copenhagen has today removed observation status for:
ISIN NAME
DK0061030574 VIROGATES
The company's observation status has been removed... ► Artikel lesen | |
| VIROGATES Aktie jetzt für 0€ handeln | |||||
| 12.11.25 | ViroGates A/S: suPAR Remedy, LLC announces the outcome of the Public Tender Offer to the shareholders of ViroGates | 164 | GlobeNewswire (Europe) | Company Announcement no. 17/2025 (November 12, 2025)
BIRKERØD, DENMARK - Today, suPAR Remedy, LLC (the "Offeror") announces the outcome of the public tender offer published on 8 October 2025 and on... ► Artikel lesen | |
| 06.11.25 | ViroGates A/S: ViroGates announces its Interim Report for Q1-Q3 2025 | 152 | GlobeNewswire (Europe) | Company Announcement no. 16/2025 (November 06, 2025)
Revenue rose 49% Y-o-Y in Q3, and total revenue for the first nine months is now slightly above the same period in 2024
BIRKERØD, DENMARK - ViroGates... ► Artikel lesen | |
| 08.10.25 | ViroGates A/S - Observation status | 189 | GlobeNewswire | Nasdaq Copenhagen has given the company below observation status:
ISIN DK0061030574 Symbol VIRO
ViroGates A/S has been given observation status, as the company has announced that suPAR... ► Artikel lesen | |
| 08.10.25 | ViroGates A/S: suPAR Remedy, LLC announces public tender offer to the shareholders of ViroGates A/S at a 40% premium | 226 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Company... ► Artikel lesen | |
| 21.08.25 | ViroGates A/S: ViroGates announces its Half-Year Report for H1 2025 | 157 | GlobeNewswire (Europe) | Company Announcement no. 10/2025 (August 21, 2025)
Revenue ending 18% below H1 2024, operating loss reduced by 26%, and proof of concept achieved for suPARnostic® POC+ in longevity
BIRKERØD, DENMARK... ► Artikel lesen | |
| 16.06.25 | ViroGates A/S: ViroGates and GENSPEED achieve proof of concept for their suPARnostic POC+ targeted at the Longevity Testing Market | 241 | GlobeNewswire (Europe) | Company Announcement no. 9/2025 (June 16, 2025)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for measuring chronic inflammation... ► Artikel lesen | |
| 21.05.25 | ViroGates A/S: Resolutions from the Extraordinary General Meeting of ViroGates A/S | 185 | GlobeNewswire (Europe) | Company Announcement no. 8/2025 (May 21, 2025)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for measuring chronic inflammation... ► Artikel lesen | |
| 01.05.25 | ViroGates A/S: ViroGates announces its Q1 report for 2025 | 160 | GlobeNewswire (Europe) | Company Announcement no. 6/2025 (May 01, 2025)
Revenue comparable to the same period last year, operating expenses reduced by 33%, and an amended agreement with Sobi
BIRKERØD, DENMARK - ViroGates A/S... ► Artikel lesen | |
| 20.03.25 | ViroGates A/S: ViroGates announces its Annual Report 2024 | 269 | GlobeNewswire (Europe) | Company Announcement no. 3/2025 (March 20, 2025)
Revenue declines by 12 % compared to last year as ViroGates continues the transition into the health- and longevity segment and fosters strategic partnerships
BIRKERØD... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 44,620 | +0,64 % | Qiagen: Das ist gewagt! | Dass die sonst zu den ruhigen DAX-Aktien gehörende Qiagen auf einmal in kurzer Zeit einen Kurssprung von in der Spitze 21 Prozent hinlegt, zieht Aufmerksamkeit auf sich. Aber könnte man der Aktie neben... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,30 | +0,01 % | H.C. Wainwright raises Praxis Precision Medicines stock price target to $1,245 | ||
| NUVALENT | 102,89 | +0,45 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| NURIX THERAPEUTICS | 16,520 | -6,08 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update | First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 14,290 | -3,77 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 25,720 | -1,30 % | Olema Oncology Announces Departure of Chief Operating and Financial Officer | SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema", or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 65,42 | -6,52 % | Apogee Therapeutics: Empfehlung liefert +129% in 6 Monaten | Im Juli letzten Jahres präsentierten wir im Rahmen unserer Berichterstattung und innerhalb unserer erfolgreichen Community die Aktie von Apogee Therapeutics als heißen Kauftipp. Grundlage war eine ausgeprägte... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 36,520 | -0,92 % | How Harmony Biosciences Can Prove Its Skeptics Wrong | ||
| STRUCTURE THERAPEUTICS | 88,44 | +1,48 % | Structure Therapeutics gains on report suggesting it may be a top takeover target | ||
| SUMMIT THERAPEUTICS | 14,460 | -6,10 % | Summit Therapeutics: FDA akzeptiert Zulassungsantrag für Lungenkrebsmedikament Ivonescimab | ||
| BIONTECH | 95,80 | -0,21 % | BASF unter DRUCK! KAUFEMPFEHLUNGEN für BioNTech und WashTec Aktie! | Marktführerschaft, Effizienzsteigerung, Dividende und Aktienrückkauf - alles gute Gründe, um die Aktie von WashTec zu kaufen. Diese Einschätzung teilen auch die Analysten von MM Warburg. Ihre Gewinnschätzungen... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 31,110 | -2,75 % | Block & Leviton LLP: Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover Losses | Boston, Massachusetts--(Newsfile Corp. - January 16, 2026) - Block & Leviton is investigating Travere Therapeutics, Inc. (NASDAQ: TVTX) for potential securities law violations. Investors who have... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,58 | +0,01 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ERASCA | 10,525 | +2,09 % | Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models | ||
| ADMA BIOLOGICS | 17,300 | +1,70 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen |
VIROGATES A/S gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,155 (+10,10 %) liegt der Kurs bei 1,690 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIROGATES A/S finden Sie auf Wallstreet Online.